Advair®

COMBINATIONS (DUO)

INHALED CORTICOSTEROID + LONG-ACTING BETA-2 AGONIST (ICS + LABA)

  • Class

    • Inhaled corticosteroid (ICS)
      Long-acting beta-2 agonist (LABA)

  • Active ingredient

    • Fluticasone propionate


    • Salmeterol (as the xinafoate salt)

  • Device

  • Age

    • 4 +
  • Typical use

    • Asthma
      uncontrolled on low dose ICS

    Asthma management principles
    • COPD
      in addition to a LAMA, when exacerbating on dual bronchodilation (LAMA/LABA)

    COPD management principles
  • Marketed strength

    • 100/50 mcg
    • 250/50 mcg
    • 500/50 mcg
  • Number of doses

    • 60 doses
  • Dose indicator

    • Yes | Numerical
  • Usual adult dosage

    • Low | 100/50 mcg – 1 inh BID
      Medium | 250/50 mcg – 1 inh BID
      High | 500/50 mcg – 1 inh BID

    ICS dosing
  • Usual pediatric dosage

    • 4-5 years 
      Not recommended

      6-11 years
      Low
      | 100/50 mcg – 1 inh QD
      Medium | 250/50 mcg – 1 inh QD

      12-17 years
      See adult dosage

    ICS dosing
  • Required inspiratory flow

    • > 30 - 60 L/min
      Medium-low internal resistance (R2)

    Inspiratory flows
  • Public coverage

    • MN | Open/Regular Benefit
      All provinces except MN | Restricted Benefit with criteria

    Provincial coverage criteria
  • Advantages

    • -
  • Disadvantages

    • BID dosing
    • Expensive
    Side effects

Product monograph

Download

Search for other inhalers